跳至主要内容
临床试验/NCT06430892
NCT06430892招募中不适用

Efficacy of the Pressure Optimization Protocol (POP )Versus Conventional Stent Deployment Strategy During Primary Percutaneous Coronary Intervention.

National Institute of Cardiovascular Diseases, Pakistan2 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2024年5月15日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
400
试验地点
2
主要终点
TIMI III flow: TIMI III flow is defined as normal flow with complete filling of the distal vascular bed.

研究概览

简要总结

Efficacy of the Pressure Optimization Protocol (POP) versus Conventional Stent Deployment Strategy during Primary PCI: An Open Label Randomized Clinical Trial The investigators will compare conventional rapid stent inflation/deflation during primary PCI with higher pressure and prolonged duration of stent deployment

Study Hypothesis: The POP in stent deployment is superior to the conventional stent deployment approach with a significantly higher achievement of the TIMI III flow, significantly lesser occurrence of slow flow/no-reflow, and significantly higher rate of ST-Segment resolution during primary PCI.

详细描述

Primary Objective The primary objective is to compare the rate of TIMI III flow achievement, slow flow/no-reflow, and ST-segment resolution between POP versus conventional stent deployment strategy during Primary PCI.

Secondary Objective The secondary objective is in-hospital outcome (to compare the rate of major adverse cardiovascular events (MACE) during hospitalization between POP versus conventional stent deployment strategy during Primary PCI.) Material and Methods Study design: An open-label randomized controlled trial (RCT) with blinded outcome assessment Setting: Cath Lab NICVD Karachi ,Hyderabad and Sukkur Duration of study: 6 months Stent Deployment Protocol: Patients will be randomly assigned to either POP or conventional stent deployment approach groups in 1:1 ratio using the block randomization method.

SAMPLE SIZE : 400 patients will be randomized into 2 groups with 1:1 Concealment: Allocation schema will remain accessible to the randomization and allocation team and will be communicated to the screening and recruitment team on a patient-on-patient basis.

Blinding: This will be an open-label study, however, the outcome assessment will be blinded. A de-identified CD and post-PCI ECG with a unique tracking ID will be evaluated by the team of independent consultants, who will be blinded to the stent placement approach, and primary outcome variables i.e. TIMI flow, slow-flow/no-reflow, and ST-segment resolution will be assessed.

Immediately post-procedure, a de-identified CD and post-PCI ECG with a unique tracking ID will be evaluated by the team of independent consultants, who will be blinded to the stent placement approach, and primary outcome variables i.e. TIMI flow, slow-flow/no-reflow, and ST-segment resolution will be assessed. All the patients will be followed at 30 days and incidence of MACE will be recorded.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

盲法说明

This will be an open-label study, however, the outcome assessment will be blinded. A de-identified CD and post-PCI ECG with a unique tracking ID will be evaluated by the team of independent consultants, who will be blinded to the stent placement approach, and primary outcome variables i.e. TIMI flow, slow-flow/no-reflow, and ST-segment resolution will be assessed

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients aged 18 years and above.
  • Patients undergoing primary percutaneous coronary intervention (PCI) with stent implantation.
  • Presence of significant coronary artery stenosis (greater than 70% diameter reduction) confirmed by angiography.

排除标准

  • Patients with Killip class IV
  • Patients with significant comorbidities such as end-stage renal disease or advanced liver disease which may interfere with the procedure or follow-up.
  • Prior history of coronary artery bypass grafting (CABG).
  • Refusal to give consent for study participation or procedure

结局指标

主要结局

TIMI III flow: TIMI III flow is defined as normal flow with complete filling of the distal vascular bed.

时间窗: periprocedurally (after stent deployment)

To assess flow in the vessel after deployment of stent

Slow-flow/no-reflow

时间窗: periprocedurally (after stent deployment)

To assess is there any Slow-flow/no-reflow phenomenon , which is TIMI flow grade \< 3 and as myocardial blushing grade (MBG) \< 2.

ST-segment resolution

时间窗: Time frame:60minutes after the procedure

Assessment of ST-segment resolution , The electrocardiographic resolution of the ST-segment elevation is defined as a reduction of \> 50% of the ST-segment elevation in the same lead within 60 min after the index procedure

次要结局

  • Cardiovascular death ( CV death)(Time frame: during hospitalization (in-hospital))
  • Myocardial infarction(Time frame: during hospitalization (in-hospital))
  • Stent thrombosis(Time frame: during hospitalization (in-hospital))
  • Cerebrovascular accident ( CVA /Stroke)(Time frame: during hospitalization (in-hospital))
  • Arrhythmias(Time frame: during hospitalization (in-hospital))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Professor Abdul Hakeem

professor

National Institute of Cardiovascular Diseases, Pakistan

研究点 (2)

Loading locations...

相似试验